| Is Part of |
Open readings 2023: 66th international conference for students of physics and natural sciences, April 18-21, 2023, Vilnius, Lithuania: annual abstract book / editors: M. Keršys, Š. Mickus.. Vilnius : Vilnius University press, 2023. p. 185.. ISBN 9786090708835 |
| Abstract [eng] |
Heterocyclic compounds, cyclic organic compounds containing at least one heteroatom, are considered to be one of the most significant classes of organic compounds that are used in many biological fields due to their diverse activity. Nitrogen, oxygen, and sulphur are the most common heteroatoms in heterocyclic compounds. These ring systems are found as major skeletons in many natural biological molecules such as hemoglobin, DNA, RNA, vitamins, hormones, etc. Heterocyclic pharmacophores constitute the biologically active fragments of many drugs used in the treatment of different diseases. Furthermore, N-heterocyclic compounds exhibit a variety of biological activities such as antifungal, antibacterial, anti-inflammatory, antioxidant, anticancer, anticonvulsant, etc. [1]. The 1,2,4-triazole ring is a structural core of compounds that exhibit multidirectional biological activity and possess a variety of biological features, including anticancer action, making it one of the most important nitrogen-containing scaffolds in medicinal chemistry [2,3]. In pharmaceutical targets, pyridine and its precursor molecule dihydropyridine are among the most prevalent structural units. In plants, they are mostly found in alkaloids. Pyridine- and dihydropyridine-containing drugs constitute nearly 14% and 4% of N-heterocyclic drugs approved by the US Food and Drug Administration (FDA). The major therapeutic areas of focus of 18% of these drugs are infectious diseases, inflammation, the nervous system, and oncology [4]. Pyridine derivatives exhibit a variety of important pharmacological activities such as antimicrobial, antimalarial, antidiabetic, and anti-inflammatory activities [5]. This work’s objective was to synthesize biologically active hybrid compounds bearing 1,2,4-triazole-3-thione and substituted pyridine moieties (Scheme 1): [...]. |
